| Similar Articles |
|---|
 |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.   |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool
April 26, 2011
Brian Orelli |
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost. |
Bio-IT World
April 15, 2003
Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. |
Chemistry World
April 27, 2011
Carol Stanier |
Drug cocktails greater than the sum of their parts Canadian scientists have shown that combining an antibiotic that is past its prime with other drugs can give it a new lease of life. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
BusinessWeek
April 21, 2011
Tom Randall |
Merck's Risky Bet on Research CEO Frazier, who made his name fighting drug lawsuits, is investing billions to churn out new medicines. |
The Motley Fool
June 29, 2011
Brian Orelli |
Doubling Up in Biotech Lilly hits multiple targets with one drug. |
The Motley Fool
May 12, 2010
Brian Orelli |
Is Merck a Buy? Short term it's hard to say, but for the long term, its pipeline looks strong. |
National Defense
June 2010
Grace V. Jean |
Research Challenge: How to Defend Against Still-Undefined Chemical, Biological Attacks Military scientists are often criticized for not working fast enough and for not pushing technologies into the field more expeditiously. Those working in chemical and biological sciences are no exception. |
Chemistry World
June 2011 |
Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most. |
Chemistry World
July 3, 2006
Mark Peplow |
Drug Screen Reveals Antimalarial Agent A widely-available antihistamine called astemizole could help in the battle against malaria, according to a survey of more than 2,600 drugs in a pharmaceutical library. |
Pharmaceutical Executive
May 1, 2001 |
On Tour with Merck's Robots Merck's HTS robots move assay plates through the screening process. |
The Motley Fool
April 6, 2011
Brian Orelli |
Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
February 3, 2011
Brian Orelli |
Get Ready for Merck's Bumpy Ride Long-term earnings guidance gets thrown out the window. |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
The Motley Fool
May 5, 2010
Brian Orelli |
Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Chemistry World
October 2010 |
Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery |
D-Lib
June 2009
Arms et al. |
EScience in Practice: Lessons from the Cornell Web Lab Anew form of scientific enquiry is emerging in which fundamental advances are made by mining information in digital formats, from datasets to digitized books. |
Chemistry World
July 2008
Kevin Rogers |
What future for small molecule therapy? Pharmaceutical companies overlook bench chemists at their peril |
The Motley Fool
December 2, 2010
Brian Orelli |
An Ounce of Prevention Gets Shot Down An FDA panel shoots down Merck's and Glaxo's prostate drugs. |
Fast Company
March 15, 2007
Tinker Ready |
Not Invented Here The next blockbuster drug could come from anywhere. It's up to Merck's scouts to find it. |
The Motley Fool
February 16, 2010
Brian Orelli |
Merck Gets a Pass, for Now Its first quarter looks promising, but not as good as could be hoped. |
D-Lib
February 2006 |
A Research Library Based on the Historical Collections of the Internet Archive As digital libraries expand, we can look forward to a day when humanities and social science scholars replace much of the tedious manual effort with computer programs. Here is a description of a library that is being built for such research. |
The Motley Fool
September 12, 2005
M.D. Mitchell |
Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch. |
BusinessWeek
November 24, 2003
John Carey |
Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells. |
The Motley Fool
June 7, 2011
Brian Orelli |
Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal. |
The Motley Fool
September 28, 2010
Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
HHMI Bulletin
February 2011 |
Viral Outbreak: The Science of Emerging Disease Almost 200 high school students from across the Washington, D.C., area learned firsthand how scientists study the emergence and spread of these and other deadly viruses in December at the 2010 Holiday Lectures on Science. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
January 21, 2011
Brian Orelli |
Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir. |
BusinessWeek
January 21, 2010
John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
The Motley Fool
May 28, 2010
Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
January 28, 2011
Luke Timmerman |
Merck, Staring at a Biotech Future, Seeks to Get in the Game With New Protein Drugs, Biosimilars Biotech drugs will soon dominate the pharmaceutical industry, and Merck is playing catch-up. |
The Motley Fool
May 18, 2010
Brian Orelli |
Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping. |
Chemistry World
June 2008
Sarah Houlton |
Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
Chemistry World
March 23, 2010 |
Comment: Can we halt the flow of new designer drugs? Could the dangers of 'legal high' mephedrone have been predicted? Of course they could, says John Mann |
Chemistry World
April 2011 |
Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
The Motley Fool
December 1, 2009
Robert Steyer |
Merck Makes a Mark on Good Cholesterol Can't profit from fighting bad lipoproteins? Start boosting the good ones. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
